ARIAD PHARMACEUTICALS INC 4

4 · ARIAD PHARMACEUTICALS INC · Filed Jun 15, 2016

Insider Transaction Report

Form 4

Period: 2016-06-13

ARIAD PHARMACEUTICALS INCARIA

LAVIDAS ATHANESE

Director

Transactions

Exercise/Conversion
Common Stock
2016-06-14$5.49/sh+10,000$54,900→ 141,631 total
Exercise/Conversion
Common Stock
2016-06-15$6.45/sh+25,000$161,250→ 171,631 total
Exercise/Conversion
Common Stock
2016-06-15$4.91/sh+6,250$30,688→ 177,881 total
Exercise/Conversion
Stock Option (Right to Buy)
2016-06-13$5.49/sh−10,000$54,900→ 10,000 total
Exercise: $5.49From: 2008-06-28Exp: 2017-06-28→ Common Stock (10,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2016-06-15$7.39/sh−15,000$110,850→ 0 total
Exercise: $7.39From: 2014-03-31Exp: 2024-01-31→ Common Stock (15,000 underlying)
Exercise/Conversion
Common Stock
2016-06-15$7.39/sh+15,000$110,850→ 146,631 total
Sale
Common Stock
2016-06-15$8.24/sh−46,250$381,137→ 131,631 total
Exercise/Conversion
Stock Option (Right to Buy)
2016-06-14$5.49/sh−10,000$54,900→ 0 total
Exercise: $5.49From: 2008-06-28Exp: 2017-06-28→ Common Stock (10,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2016-06-14$7.39/sh−10,000$73,900→ 15,000 total
Exercise: $7.39From: 2014-03-31Exp: 2024-01-31→ Common Stock (10,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2016-06-15$4.91/sh−6,250$30,688→ 18,750 total
Exercise: $4.91From: 2016-03-31Exp: 2026-02-01→ Common Stock (6,250 underlying)
Exercise/Conversion
Common Stock
2016-06-13$5.49/sh+10,000$54,900→ 141,631 total
Sale
Common Stock
2016-06-13$8.21/sh−10,000$82,050→ 131,631 total
Exercise/Conversion
Common Stock
2016-06-14$7.39/sh+10,000$73,900→ 151,631 total
Sale
Common Stock
2016-06-14$8.14/sh−20,000$162,852→ 131,631 total
Exercise/Conversion
Stock Option (Right to Buy)
2016-06-15$6.45/sh−25,000$161,250→ 0 total
Exercise: $6.45From: 2015-03-31Exp: 2025-01-31→ Common Stock (25,000 underlying)

Footnotes (9)

[F1]The shares were acquired and sold upon exercise of stock options that would have expired on 10/21/2016 (three months following termination of service as a director), in which event the reporting person would have lost the right to acquire the shares underlying the options.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.20 to $8.21, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.13 to $8.155, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote.
[F4]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.23 to $8.265, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote.
[F5]The stock options were granted on 06/28/2007 and vested in three annual installments commencing on 06/28/2008.
[F6]The stock options would have expired on 10/21/2016 (three months following termination of service as a director), in which event the holder would have lost the right to acquire the shares underlying the options.
[F7]The stock options were granted on 01/31/2014 and vested as to one-fourth of the options in quarterly installments commencing on March 31, 2014.
[F8]The stock options were granted on 01/31/2015 and vested as to one-fourth of the options in quarterly installments commencing on March 31, 2015.
[F9]The stock options were granted on 02/01/2016 and vest as to one-fourth of the options in quarterly installments commencing on March 31, 2016.

Documents

3 files

4
wf-form4_146602195031615.xmlPrimary
FORM 4
EX-24
lavidas.htm
LAVIDAS POA
GRAPHIC
lavidas001.jpg
LAVIDAS